CALCRL and migraine disorder: Additionally, antibodies against CGRP or CGRPR (e.g., eptinezumab, fremanezumab, galcanezumab, and erenumab), as well as small-molecule CGRPR antagonists (“gepants”, e.g., atogepant, rimegepant, and ubrogepant), are available for the prevention or the therapy of migraines, respectively [8,10,12].